Systemic chemotherapeutic treatment of patients with breast cancer brain metastases

Любота, Р. В.; Верещако, Р.; Anikusko, Mykola; Любота, И И; Vakulenko, G. Yu.

doi:10.32471/exp-oncology.2312-8852.vol-43-no-2.16249

Cited by 1 publication

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Local stereotactic radiosurgery (SRS) and whole-brain radiotherapy (WBRT) result in early and late neurotoxicity, without any considerable improvement in OS [16,[104][105][106]. Standard systemic chemotherapy has been observed to increase OS in BCBM patients compared with no chemotherapy [107,108], but an increase in the rate of metastatic progression has also been reported. However, these reports lack clarification of the direct effect of the systematic approach on BCBM [107,108].…”

Section: Current Treatments and Therapies For Bcbmmentioning

confidence: 99%

“…Standard systemic chemotherapy has been observed to increase OS in BCBM patients compared with no chemotherapy [107,108], but an increase in the rate of metastatic progression has also been reported. However, these reports lack clarification of the direct effect of the systematic approach on BCBM [107,108]. As well, a low treatment efficacy was also observed using immunotherapy alone or associated with other treatment approaches.…”

Section: Current Treatments and Therapies For Bcbmmentioning

confidence: 99%

See 1 more Smart Citation

Navigating the Blood–Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases

Terceiro

Ikeogu

Lima

et al. 2023

IJMS

View full text Add to dashboard Cite

Breast cancer (BC) is the most common cancer in women, with metastatic BC being responsible for the highest number of deaths. A frequent site for BC metastasis is the brain. Brain metastasis derived from BC involves the cooperation of multiple genetic, epigenetic, angiogenic, and tumor–stroma interactions. Most of these interactions provide a unique opportunity for development of new therapeutic targets. Potentially targetable signaling pathways are Notch, Wnt, and the epidermal growth factor receptors signaling pathways, all of which are linked to driving BC brain metastasis (BCBM). However, a major challenge in treating brain metastasis remains the blood–brain barrier (BBB). This barrier restricts the access of unwanted molecules, cells, and targeted therapies to the brain parenchyma. Moreover, current therapies to treat brain metastases, such as stereotactic radiosurgery and whole-brain radiotherapy, have limited efficacy. Promising new drugs like phosphatase and kinase modulators, as well as BBB disruptors and immunotherapeutic strategies, have shown the potential to ease the disease in preclinical studies, but remain limited by multiple resistance mechanisms. This review summarizes some of the current understanding of the mechanisms involved in BC brain metastasis and highlights current challenges as well as opportunities in strategic designs of potentially successful future therapies.

show abstract